Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
18.68
-0.23 (-1.22%)
Mar 20, 2026, 3:00 PM CST
Market Cap30.87B -6.2%
Revenue (ttm)24.18B -5.4%
Net Income1.43B -26.9%
EPS0.87 -26.6%
Shares Out1.63B
PE Ratio21.64
Forward PE13.29
Dividend0.47 (2.45%)
Ex-Dividend DateAug 19, 2025
Volume15,154,977
Average Volume16,210,835
Open18.91
Previous Close18.91
Day's Range18.68 - 19.13
52-Week Range16.73 - 23.66
Beta0.54
RSI43.83
Earnings DateMar 31, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements